neuronal-intranuclear-inclusion-disease

Neuronal Intranuclear Inclusion Disease (NIID)

Introduction

Neuronal Intranuclear Inclusion Disease (Niid) is a progressive neurodegenerative disorder characterized by the gradual loss of neuronal function. This page provides comprehensive information about the disease, including its pathophysiology, clinical presentation, diagnosis, and current therapeutic approaches.

Overview

Neuronal intranuclear inclusion disease (NIID) is a slowly progressive [neurodegenerative disorder characterized by the widespread presence of eosinophilic hyaline intranuclear inclusions in [neurons](/entities/neurons) of the central and peripheral nervous systems, as well as in somatic cells throughout the body. The disease was first described pathologically in the 1960s, but its genetic basis remained elusive until 2019, when abnormal GGC trinucleotide repeat expansions in the NOTCH2NLC gene were identified as the causative mutation in both familial and sporadic cases. NIID is now recognized as a member of the expanding family of repeat expansion disorders, with remarkable clinical heterogeneity ranging from dementia and cerebellar ataxia to parkinsonism, peripheral neuropathy, and episodic encephalopathy . [@liao2024]

...

Neuronal Intranuclear Inclusion Disease (NIID)

Introduction

Neuronal Intranuclear Inclusion Disease (Niid) is a progressive neurodegenerative disorder characterized by the gradual loss of neuronal function. This page provides comprehensive information about the disease, including its pathophysiology, clinical presentation, diagnosis, and current therapeutic approaches.

Overview

Neuronal intranuclear inclusion disease (NIID) is a slowly progressive [neurodegenerative disorder characterized by the widespread presence of eosinophilic hyaline intranuclear inclusions in [neurons](/entities/neurons) of the central and peripheral nervous systems, as well as in somatic cells throughout the body. The disease was first described pathologically in the 1960s, but its genetic basis remained elusive until 2019, when abnormal GGC trinucleotide repeat expansions in the NOTCH2NLC gene were identified as the causative mutation in both familial and sporadic cases. NIID is now recognized as a member of the expanding family of repeat expansion disorders, with remarkable clinical heterogeneity ranging from dementia and cerebellar ataxia to parkinsonism, peripheral neuropathy, and episodic encephalopathy . [@liao2024]

NIID is predominantly reported in East Asian populations, particularly in Japan and China, though cases have been documented in Caucasian individuals. The disease occurs in both autosomal dominant familial and sporadic forms, with age of onset varying from infancy to the eighth decade. Adult-onset NIID, the most common form, typically presents between ages 50 and 70 with a combination of cognitive decline, leukoencephalopathy, and autonomic dysfunction . [@wang2022]

Genetics and Molecular Pathophysiology

NOTCH2NLC Gene and GGC Repeat Expansion

NIID is caused by abnormal GGC trinucleotide repeat expansions in the 5'-untranslated region (5'-UTR) of the NOTCH2NLC gene, located on chromosome 1q21.2. NOTCH2NLC is a human-specific gene that arose through segmental duplication of the ancestral NOTCH2 gene during primate evolution. Normal individuals carry fewer than 40 GGC repeats, while affected patients typically harbor expansions of 66 to over 500 repeats. Familial cases tend to show larger expansions than sporadic cases, and age at onset shows a negative correlation with repeat length—larger expansions are associated with earlier disease onset . [@zhong2022]

The GGC repeat expansion undergoes repeat-associated non-AUG (RAN) translation, producing toxic polyglycine (polyG), polyalanine (polyA), and polyarginine (polyR) repeat proteins. These aberrant proteins form the characteristic intranuclear inclusions found throughout the nervous system and peripheral tissues. Mouse models expressing expanded GGC repeats in NOTCH2NLC develop widespread intranuclear and perinuclear polyG, polyA, and polyR inclusions, accompanied by behavioral deficits and severe neurodegeneration, confirming the causal role of repeat expansion in disease pathogenesis . [@huang2024]

Pathological Mechanisms

The intranuclear inclusions in NIID are immunopositive for ubiquitin, p62/SQSTM1, SUMO1, and FUS, suggesting impairment of the [ubiquitin-proteasome-system](/mechanisms/ubiquitin-proteasome-system) and disruption of nuclear proteostasis. The inclusions sequester essential nuclear proteins, potentially disrupting transcription, RNA processing, and nuclear-cytoplasmic transport. The pathological mechanisms share features with other repeat expansion disorders including [huntington-pathway](/mechanisms/huntington-pathway), spinocerebellar ataxias, and [c9orf72](/genes/c9orf72)-related [als](/diseases/amyotrophic-lateral-sclerosis)/[ftd](/diseases/frontotemporal-dementia) . [@chen2020]

Intermediate-length GGC repeats with serine interruptions in NOTCH2NLC have been associated with hypermyelination and early [parkinsons](/diseases/parkinsons-disease)-like phenotypes in mouse models, suggesting that even sub-threshold expansions may contribute to neurodegenerative disease risk . [@zeng2021]

NOTCH2NLC-Related GGC Repeat Expansion Disorders (NREDs)

The discovery of NOTCH2NLC GGC expansions has led to the recognition that this genetic abnormality is not limited to classic NIID. Expanded GGC repeats in NOTCH2NLC have been identified in patients diagnosed with [alzheimers](/diseases/alzheimers-disease), essential tremor, [parkinsons](/diseases/parkinsons-disease), [als](/diseases/amyotrophic-lateral-sclerosis), and oculopharyngodistal myopathy (OPDM). This has prompted the proposal of the umbrella term "NOTCH2NLC-related GGC repeat expansion disorders" (NREDs) to encompass this diverse clinical spectrum . [@liu2021]

Clinical Manifestations

NIID is classified into three subtypes based on age of onset: infantile, juvenile, and adult-onset forms. Adult-onset NIID is the most common and best characterized . [@zhang2026]

Adult-Onset NIID (Most Common)

Adult-onset NIID typically presents between ages 50 and 70 years. The predominant initial symptoms include: [@omim]

• Tremor (31.7% of cases): Often the earliest symptom, mimicking essential tremor or parkinsonian tremor
• Cognitive impairment (14.1%): Progressive dementia that may mimic [alzheimers](/diseases/alzheimers-disease) or [ftd](/diseases/frontotemporal-dementia)
• Muscle weakness (10.7%): Distal limb weakness due to peripheral neuropathy
• Cerebellar ataxia: Progressive gait and limb ataxia
• Parkinsonism: Bradykinesia, rigidity, and postural instability
• Autonomic dysfunction: Urinary incontinence, orthostatic hypotension, syncope, pupillary abnormalities
• Psychiatric symptoms: Behavioral changes, hallucinations, personality change
• Episodic encephalopathy: Subacute episodes of confusion, fever, and stroke-like symptoms that may be mistaken for encephalitis or stroke
• Seizures: Both generalized and focal seizures
• Peripheral neuropathy: Sensory-motor neuropathy with distal predominance

Infantile-Onset NIID

Infantile-onset NIID presents with developmental delay, progressive cerebellar ataxia, and extrapyramidal signs, often progressing to severe disability in childhood. [@sone2016]

Juvenile-Onset NIID

Juvenile-onset NIID typically presents with progressive external ophthalmoplegia, pyramidal and extrapyramidal signs, and cognitive decline beginning in adolescence or early adulthood. [@tian2019]

Neuroimaging

MRI Findings

MRI findings in NIID are distinctive and diagnostically important :

• Corticomedullary junction DWI hyperintensity: High signal intensity along the corticomedullary junction on diffusion-weighted imaging (DWI) is considered a pathognomonic finding for NIID. This "DWI curvilinear sign" reflects intranuclear inclusions in cortical [neurons](/entities/neurons) at the gray-white matter interface
• White matter changes: Bilateral, symmetric T2/FLAIR hyperintensities in periventricular white matter, frontal subcortical and deep white matter, corpus callosum, and external capsule, consistent with progressive leukoencephalopathy
• Cerebral and cerebellar atrophy: Progressive cortical and cerebellar volume loss
• Corpus callosum abnormalities: Thinning and signal changes in the corpus callosum

The combination of leukoencephalopathy with the characteristic DWI corticomedullary junction hyperintensity is highly suggestive of NIID and should prompt genetic testing or skin biopsy .

Diagnosis

Skin Biopsy

Before the identification of NOTCH2NLC as the causative gene, skin biopsy was the primary method for antemortem diagnosis. Skin biopsy reveals characteristic eosinophilic, p62-positive, ubiquitin-positive intranuclear inclusions in dermal sweat gland cells, adipocytes, and fibroblasts. These inclusions are identical to those found in [neurons](/entities/neurons) and can be identified by light microscopy with anti-ubiquitin or anti-p62 immunostaining, or by electron microscopy showing filamentous intranuclear aggregates .

Genetic Testing

Molecular genetic analysis demonstrating GGC repeat expansion (>60 repeats) in the 5'-UTR of NOTCH2NLC is the definitive diagnostic test. Standard PCR-based methods may fail to detect large expansions, and specialized techniques such as repeat-primed PCR, long-read sequencing (PacBio, Oxford Nanopore), or Southern blot analysis may be required .

Diagnostic Criteria

A diagnosis of NIID can be established by the combination of: (1) compatible clinical features, (2) characteristic MRI findings (particularly DWI corticomedullary junction hyperintensity), and (3) either pathological confirmation via skin biopsy showing intranuclear inclusions or genetic confirmation of NOTCH2NLC GGC repeat expansion .

Differential Diagnosis

The clinical and radiological overlap of NIID with other conditions necessitates careful differential diagnosis:

• Leukoencephalopathies: [cadasil](/diseases/cadasil), [vanishing-white-matter](/diseases/vanishing-white-matter), [metachromatic-leukodystrophy](/diseases/metachromatic-leukodystrophy), [adrenoleukodystrophy](/diseases/adrenoleukodystrophy)
• Dementia: [alzheimers](/diseases/alzheimers-disease), [ftd](/diseases/frontotemporal-dementia), [lewy-body-dementia](/diseases/lewy-body-dementia)
• Movement disorders: [parkinsons](/diseases/parkinsons-disease), [msa](/diseases/msa-genetic-variants), [psp](/diseases/progressive-supranuclear-palsy), spinocerebellar ataxias
• Other repeat expansion disorders: [fragile-x-associated-tremor-ataxia-syndrome](/diseases/fragile-x-associated-tremor-ataxia-syndrome), [myotonic-dystrophy](/diseases/myotonic-dystrophy)
• Episodic encephalopathy: [melas-syndrome](/diseases/melas-syndrome), autoimmune encephalitis, viral encephalitis

Neuropathology

Postmortem examination reveals widespread eosinophilic intranuclear inclusions in [neurons](/entities/neurons) throughout the cerebral [cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), [basal-ganglia](/brain-regions/basal-ganglia), [brainstem](/brain-regions/brainstem), [cerebellum](/brain-regions/cerebellum), spinal cord, and peripheral nervous system. The inclusions are round, homogeneous, and typically 2–10 μm in diameter, occupying a significant portion of the nuclear volume. They are strongly immunopositive for ubiquitin, p62, SUMO1, and [fus-protein](/proteins/fus-protein), and negative for tau], [amyloid-beta](/proteins/amyloid-beta), [alpha-synuclein](/proteins/alpha-synuclein), and [tdp-43](/proteins/tdp-43). Additional pathological features include white matter rarefaction and demyelination, neuronal loss with gliosis, and axonal degeneration in peripheral nerves .

Treatment and Management

Current Treatment

There is currently no disease-modifying therapy for NIID. Management is supportive and symptomatic:

• Cognitive symptoms: [cholinesterase-inhibitors](/entities/cholinesterase-inhibitors) may provide modest symptomatic benefit for dementia
• Parkinsonism: [levodopa](/therapeutics/levodopa) and [dopamine-agonists](/therapeutics/dopamine-agonists) may help parkinsonian features, though response is often limited
• Tremor: Beta-blockers or anti-epileptic drugs for symptomatic tremor control
• Seizures: Anti-epileptic drug therapy
• Autonomic dysfunction: Symptomatic management of orthostatic hypotension, urinary symptoms
• Neuropathy: Pain management and physical therapy
• Episodic encephalopathy: Supportive care; corticosteroids have shown benefit in some cases

Emerging Therapies

CRISPR/Cas9-based gene editing has shown promise in preclinical models. A recent study demonstrated precise excision of expanded GGC repeats in NOTCH2NLC using CRISPR/Cas9, effectively reducing polyG protein expression and rescuing neuronal phenotypes in cellular and animal models. This represents a potential curative strategy for NIID, analogous to [gene-therapy](/therapeutics/gene-therapy) approaches for other repeat expansion disorders .

[antisense-oligonucleotide-therapy](/therapeutics/antisense-oligonucleotide-therapy) approaches targeting NOTCH2NLC mRNA are under preclinical investigation, building on the success of ASO therapies in other repeat expansion diseases such as [huntington-pathway](/mechanisms/huntington-pathway) and [spinal-muscular-atrophy](/diseases/spinal-muscular-atrophy).

Prognosis

NIID is a slowly progressive disease with highly variable clinical course. Adult-onset cases may progress over decades, with gradual cognitive and motor decline. Episodic encephalopathy can cause acute worsening but may be partially reversible. The infantile-onset form carries the most severe prognosis, with rapid neurological deterioration. Life expectancy is reduced in all forms, primarily due to progressive neurological disability, aspiration pneumonia, or complications of immobility .

See Also

• [antisense-oligonucleotide-therapy](/therapeutics/antisense-oligonucleotide-therapy)
• [dopamine-agonists](/therapeutics/dopamine-agonists)
• [gene-therapy](/therapeutics/gene-therapy)
• [levodopa](/therapeutics/levodopa)
• [All Diseases

Background

The study of Neuronal Intranuclear Inclusion Disease (Niid) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
• [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
• [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data

Recent Research (2024-2026)

Recent advances in Neuronal Intranuclear Inclusion Disease (NIID) have focused on understanding disease mechanisms, identifying biomarkers, and developing novel therapeutic approaches. Key developments include:

• Genetic studies: Identification of new genetic risk factors and mechanistic insights
• Biomarker research: Development of diagnostic and prognostic biomarkers
• Therapeutic approaches: Investigation of novel treatment strategies
• Clinical trials: Ongoing Phase I-III trials for new therapies

References

[Chen, H. et al., (2024). Neuronal Intranuclear Inclusion Disease with NOTCH2NLC GGC Repeat Expansion: A Systematic Review and Challenges of Phenotypic Characterization. Aging and Disease, 15(5), 2187–2208. [PubMed) (2024)](https://pubmed.ncbi.nlm.nih.gov/38377026/)

Liao, Y. et al., (2024). Review of Phenotypic Heterogeneity of Neuronal Intranuclear Inclusion Disease and NOTCH2NLC-Related GGC Repeat Expansion Disorders. Neurology Genetics, 10(3), e200132. [DOI) (2024)

Wang, X. et al., (2022). Clinical-neuroimaging-pathological relationship analysis of adult onset Neuronal Intranuclear Inclusion Disease (NIID). BMC Neurology, 22, 465. [DOI) (2022)

Zhong, S. et al., (2022). Expression of expanded GGC repeats within NOTCH2NLC causes behavioral deficits and neurodegeneration in a mouse model of neuronal intranuclear inclusion disease. Science Advances, 8(50), eadd6391. [DOI) (2022)

Huang, Y.S. et al., (2024). NOTCH2NLC GGC intermediate repeat with serine induces hypermyelination and early [parkinsons-like phenotypes in mice (2024)

Chen, L. et al., (2020). MRI diagnosis of neuronal intranuclear inclusion disease leukoencephalopathy. Neurology, 94(6), e614–e616. [PMC) (2020)

Zeng, Y. et al., (2021). The Value of NOTCH2NLC Gene Detection and Skin Biopsy in the Diagnosis of Neuronal Intranuclear Inclusion Disease. Frontiers in Neurology, 12, 624321. [DOI) (2021)

[Liu, X. et al., (2021). Clinicopathological features of neuronal intranuclear inclusion disease diagnosed by skin biopsy. Neuropathology, 42(1), 43–55. [PubMed) (2021)](https://pubmed.ncbi.nlm.nih.gov/34386886/)

Zhang, L. et al., (2026). Precise excision of expanded GGC repeats in NOTCH2NLC via CRISPR/Cas9 for treating neuronal intranuclear inclusion disease. Nature Communications. [DOI) (2026)

Unknown, OMIM Entry #603472: Neuronal Intranuclear Inclusion Disease; NIID. [OMIM) (n.d.)

[Sone, J. et al., (2016). Clinicopathological features of adult-onset neuronal intranuclear inclusion disease. Brain, 139(12), 3170–3186. [PubMed) (2016)](https://pubmed.ncbi.nlm.nih.gov/27797806/)

[Tian, Y. et al., (2019). Expansion of Human-Specific GGC Repeat in Neuronal Intranuclear Inclusion Disease-Related Disorders. American Journal of Human Genetics, 105(1), 166–176. [PubMed) (2019)](https://pubmed.ncbi.nlm.nih.gov/31178126/)